Propentofylline

Last updated
Propentofylline
Propentofylline.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
  • 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1H-purine-2,6-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.133.568 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C15H22N4O3
Molar mass 306.366 g·mol−1
3D model (JSmol)
  • CCCn1cnc2c1c(=O)n(c(=O)n2C)CCCCC(=O)C
  • InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
  • Key:RBQOQRRFDPXAGN-UHFFFAOYSA-N
   (verify)

Propentofylline (HWA 285) is a xanthine derivative drug with purported neuroprotective effects.

Contents

Pharmacology

It is a phosphodiesterase inhibitor, [1] and also acts as an adenosine reuptake inhibitor. [1] [2] [3]

Uses

Propentofylline was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia, [1] [4] and has been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties. [5] [6]

Propentofylline is in use as a veterinary medicine in older dogs. [7]

See also

References

  1. 1 2 3 Frampton M, Harvey RJ, Kirchner V (2003). Frampton MA (ed.). "Propentofylline for dementia". The Cochrane Database of Systematic Reviews (2) CD002853. doi:10.1002/14651858.CD002853. PMID   12804440.
  2. ↑ Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID   18096287. S2CID   21498202.
  3. ↑ Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi: 10.1016/S0306-4522(97)00542-3 . PMID   9578400. S2CID   36155779.
  4. ↑ Kittner B, Rössner M, Rother M (September 1997). "Clinical trials in dementia with propentofylline". Annals of the New York Academy of Sciences. 826 (1): 307–316. Bibcode:1997NYASA.826..307K. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID   9329701. S2CID   12493243.
  5. ↑ Bath PM, Bath-Hextall FJ (2004). Bath PM (ed.). "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (3) CD000162. doi:10.1002/14651858.CD000162.pub2. PMID   15266424.
  6. ↑ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (May 1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". Journal of Cerebral Blood Flow and Metabolism. 13 (3): 526–530. doi:10.1038/jcbfm.1993.68. PMID   8478410. S2CID   24909748.
  7. ↑ "Launch of tablet to make life easier for dogs in old age". Yorkshire Post. 7 September 2012. Retrieved 28 December 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.